Nasdaq GlobeNewswire

Newly Formed Elixinol Global Begins Trading on Australian Stock Exchange

Del

Colorado-Based Elixinol LLC, joins forces with Hemp Foods Australia and Elixinol Australia to form Elixinol Global

SYDNEY, Australia, Jan. 09, 2018 (GLOBE NEWSWIRE) -- Intending to serve the growing global cannabis market, Elixinol Global (ASX: EXL), comprised of Elixinol LLC, with distribution of hemp-based CBD products in 27 countries, Hemp Foods Australia and Elixinol Pty.  Elixinol Global provides investors with access to global markets in the emerging sectors of hemp-based dietary supplements and skin care, hemp food products and medical cannabis products.

Elixinol Global began trading on the Australian Stock Exchange starting January 8, 2018.

"With global exports of Australian medical marijuana now approved, the world will soon have single-source access to best in class medical marijuana and hemp products from Elixinol, one of the world's most trusted brands," said Paul Benhaim, CEO of Elixinol Global.

"Paul Benhaim, widely recognized as one of the earliest global hemp advocates, is a founder in all three companies. It is time to offer investors an opportunity to take advantage of the collective footprint in this revolutionary emerging global market while capitalizing on potential efficiencies," said Ron Dufficy, Elixinol Global's Chief Financial Officer.

Under the new organization, Australian-based Hemp Foods will continue to be a global manufacturer and distributor of quality hemp food products and skin care. Elixinol LLC will continue to be the global bulk and retail provider of hemp-based cannabidiol (CBD) dietary supplements and topical products from US and European hemp. Elixinol Pty will provide the globe access to medical marijuana exports from Australia.

"As the cannabis market grows, it will be ever important to health-conscious consumers to know and trust their CBD and THC products. Elixinol LLC and Hemp Foods have been leading the industry with best in class sourcing and testing since their respective inceptions and Elixinol Pty will provide the same assurances for global medical marijuana patients," said Benhaim

"This means our global customers will see increased access to the same great products they're using in their daily lives, with a continued focus on research and development of new products that meet the demands of active, healthy lifestyles," continued Benhaim.

"We've worked very hard to make Elixinol the most trusted CBD brand in the world Elixinol Global is only the beginning of expanded opportunities for investors, strategic partners and our global customers," continued Benhaim.

Forward-Looking Information: This news release contains "forward-looking information" within the meaning of applicable securities laws relating to statements regarding the Company's business, products and future the Company's business, its product offerings and plans for sales and marketing. Although the Company believes that the expectations reflected in the forward looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned to not place undue reliance on forward-looking information. Such forward looking statements are subject to risks and uncertainties that may cause actual results, performance and developments to differ materially from those contemplated by these statements depending on, among other things, the risks that the Company's products and plan will vary from those stated in this news release and the Company may not be able to carry out its business plans as expected. Except as required by law, the Company expressly disclaims any obligation, and does not intend, to update any forward looking statements or forward-looking information in this news release. Although the Company believes that the expectations reflected in the forward looking information are reasonable, there can be no assurance that such expectations will prove to be correct and makes no reference to profitability based on sales reported. The statements in this news release are made as of the date of this release.

The ASX has not reviewed, approved or disapproved the content of this press release.     

About Elixinol Global
Elixinol Global is publically traded on the ASX under ELX.  The holding company has a global presence in the cannabis industry including hemp, CBD dietary supplements, food and wellness products, as well as the cultivation and manufacture of medicinal cannabis products. Elixinol Global's brands include:  Elixinol LLC, founded in 2014, is a global manufacturer and distributor of industrial hemp based dietary supplement and skincare products, with operations based out of Colorado, USA Founded in 1999, Hemp Foods Australia Pty Ltd is the largest hemp food wholesaler, retailer, manufacturer and exporter in the Southern Hemisphere of bulk and branded raw materials and finished products. Elixinol Pty Ltd, founded in 2014, to participate in the emerging Australian medicinal cannabis market.

Media Contacts:

Paul Benhaim
Chief Executive Officer
paul@elixinolglobal.com
+61 407 767 709

Ron Dufficy
Chief Financial Officer and Company Secretary
+61 428 881 718
ron.dufficy@elixinolglobal.com

Photos accompanying this announcement are available at

http://www.globenewswire.com/NewsRoom/AttachmentNg/0710ed06-3e47-4081-82cd-13a0e6753067

http://www.globenewswire.com/NewsRoom/AttachmentNg/87b4ca90-7923-4072-a5f9-b6a8e9a887e7 




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Elixinol via Globenewswire

Om Nasdaq GlobeNewswire

Nasdaq GlobeNewswire
Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

+1 212 401 8700http://www.nasdaqomx.com

NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.

Følg saker fra Nasdaq GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Nasdaq GlobeNewswire

Paper in Scientific Reports Highlights Ability of 4D Pharma’s MRx0004 to Protect Against Airway Inflammation in Severe Asthma14.8.2018 08:00Pressemelding

Data suggest that MRx0004 is a promising next-generation therapeutic for management of asthma LEEDS, United Kingdom, Aug. 14, 2018 (GLOBE NEWSWIRE) -- 4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of live biotherapeutics, today announces the publication of a paper demonstrating that MRx0004, a live biotherapeutic derived from the human gut microbiome, can protect against airway inflammation by reducing both neutrophilic and eosinophilic infiltration in a mouse model of severe asthma. The paper “Bifidobacterium breve MRx0004 protects against airway inflammation in a severe asthma model by suppressing both neutrophil and eosinophil lung infiltration” (Raftis et al.) is published in the Nature Publishing Group journal Scientific Reports . Asthma is a phenotypically heterogeneous disease. Between 5-10 % of asthma patients have a severe form of the disease which is refractory to steroid treatment and whose symptoms cannot be controlled despite the application o

Bombardier Continues African Market Penetration with Pre-Owned Q40013.8.2018 17:19Pressemelding

PassionAir becomes first Bombardier operator in Ghana with three Q400 aircraft MONTREAL, Aug. 13, 2018 (GLOBE NEWSWIRE) -- Bombardier Commercial Aircraft announced today that the company successfully placed three pre-owned Q400 turboprops with PassionAir from the Republic of Ghana. The airline acquired the aircraft through a dry-lease with a third party. “Bombardier has sold about 3,500 new regional aircraft to date, and we continue to be very active on the used aircraft market.” said David Speirs, Vice President, Asset Management, Bombardier Commercial Aircraft. “Our recent momentum on the pre-owned aircraft market worldwide is a clear indication that our products are addressing a growing need for regional air transportation, especially in emerging markets.” “Our market penetration in Africa continues to intensify, and we are pleased to welcome Passion Air as the first commercial airline operating a Bombardier regional aircraft in the Republic of Ghana,” said Jean-Paul Boutibou, Vice

SEMAFO: Armed Incident in Est Region13.8.2018 17:09Pressemelding

MONTREAL, Aug. 13, 2018 (GLOBE NEWSWIRE) -- SEMAFO Inc. (TSX, OMX: SMF) regrets to report that an armed incident occurred between the town of Fada and the Boungou Mine site in the Est region of Burkina Faso. As a result, five gendarmes and one sub-contractor employee lost their lives. Operations at the Boungou Mine were not affected. As a precautionary measure, we will be increasing our security measures and continue to closely monitor the situation with our partners to protect the safety of SEMAFO employees and our operations. The Corporation would like to express its deepest sympathy to families of the victims. About SEMAFO SEMAFO is a Canadian-based mining company with gold production and exploration activities in West Africa. The Corporation operates the Mana Mine in Burkina Faso, which includes the high-grade satellite deposit of Siou, and is targeting commercial production at the Boungou Mine in the third quarter of 2018. SEMAFO is committed to evolve in a conscientious manner to

Checkpoint Therapeutics Announces Clinical Data on EGFR Inhibitor CK-101 Selected for Late-Breaking Oral Presentation at IASLC 19th World Conference on Lung Cancer13.8.2018 14:00Pressemelding

NEW YORK, Aug. 13, 2018 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immuno-oncology biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for patients with solid tumor cancers, today announced that preliminary safety and efficacy data from a Phase 1/2 clinical trial of CK-101 (also known as RX518), a third-generation epidermal growth factor receptor (“EGFR”) tyrosine kinase inhibitor (“TKI”) being evaluated in advanced non-small cell lung cancer, has been selected for a late-breaking oral presentation at the International Association for the Study of Lung Cancer (IASLC) 19th World Conference on Lung Cancer, to be held September 23-26, 2018, in Toronto. "We are thrilled to announce that preliminary data from the Phase 1/2 trial of our novel third-generation EGFR inhibitor has been selected for a late-breaking oral presentation at the World Conference on Lung Cancer. This marks the

Mash Group Plc reports interim unaudited financials, H1 2018 ended 30th June 201813.8.2018 08:00Pressemelding

Mash Group reports record H1/18 revenue, up 99% from H1/17. With H1/18 lending volumes surpassing full year 2017 and a strong EBIT of EUR 5.5 million achieved, Mash Group is extremely well positioned to continue executing on its growth plan, comments CEO Hickson . Mash continued to grow rapidly in all markets during the second quarter, achieving record lending volumes and maintaining strong momentum. Strategic Highlights Mash increases the size of its structured financing facility with funds managed by affiliates of Fortress Investment Group LLC (NYSE:FIG), from EUR 120 million to EUR 200 million. Mash was recognized as one of the Fintech50, Europe’s leading list of FinTech companies. AI Global Media, award CEO Hickson ‘Most Influential FinTech CEO of the year 2018’. Operational Highlights Mash continued to grow rapidly in all markets during the second quarter, achieving a record Q2 2018 in terms of lending volumes (+27%) and revenues (+36%) compared to Q1 2018. Registered merchants fo

ATPCO Awarded Patent for Cacheless Airline Ticket Pricing Model13.8.2018 06:00Pressemelding

Establishes Technology Foundational to Next-Gen Airline Revenue Management Tools DULLES, Va., Aug. 13, 2018 (GLOBE NEWSWIRE) -- ATPCO today announced that it has been awarded Patent #10,032,195 by the United States Patent and Trademark Office to cover new technology, developed by its data scientists and technical architects, that enables construction of airline ticket prices using graph database and “functional programming” techniques. This technology permits a unique approach to calculating airfare prices that was not previously available. Airline ticket prices are built using diverse individual data components: fares, flight schedules, taxes, and various legal and governance structures. An airline also sets business restrictions, known as rules, to determine under what circumstances a fare may be offered, such as requiring a Saturday-night stay or during pre-determined promotional sale dates. All these elements must be referenced and incorporated into the final price of an airline ti

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom